Horizon Therapeutics (HZNP) Tops Q1 EPS by 18c, Raises FY Rev. Guidance

Go back to Horizon Therapeutics (HZNP) Tops Q1 EPS by 18c, Raises FY Rev. Guidance

Horizon Therapeutics plc Reports Strong First-Quarter 2020 Financial Results; Increasing TEPEZZA™ Full-Year 2020 Net Sales Guidance to Greater Than $200 Million Due to Rapid Uptake; Increasing Full-

May 6, 2020 7:00 AM EDT

-- First-Quarter 2020 Net Sales of $355.9 Million Increased 27 Percent;
First-Quarter 2020 GAAP Net Loss of $13.6 Million; Adjusted EBITDA of $107.2 Million --

-- Orphan Segment First-Quarter 2020 Net Sales of $245.4 Million, an Increase of 47 Percent;
KRYSTEXXA® First-Quarter 2020 Net Sales of $93.3 Million, an Increase of 78 Percent --

-- TEPEZZA (teprotumumab-trbw) First-Quarter 2020 Net Sales of $23.5 Million Driven by
Strong Demand and Launch Execution, Significantly Exceeding Expectations;
Increasing Full-Year 2020 Guidance to Greater Than $200 Million from $30 Million to $40 Million --

-- Increasing Full-Year 2020 Net Sales Guidance to $1.40 to $1.45... More